Sakarya Tıp Dergisi (Mar 2019)
Comparison of intravitreal ranibizumab and diod laser photocoagulation treatment for retinopathy of prematurity; effects on axial lenght and refractive status
Abstract
Objective: To evaluate the effects of diode laser photocoagulation and intravitreal ranibizumab (IVR) treatments on axial lenght and refractive status development in the treatment of retinopathy of premautrity (ROP). Materials and methods: The study included 82 eyes of 41 patients who were 1 year adjusted age, underwent primarily diode laser photocoagulation or 0.25 mg/0.025 ml IVR. Axial lenght (AL) and spherical equivalent (SE) parameters were compared. Results: Patients divided into two groups. Group 1 had 34 eyes of 17 patients who underwent IVR treatment and group 2 had 48 eyes of 24 patients who underwent diode laser photocoagulation treatment. In group 1, AL were detected 19,86 ±1,104mm in right eyes and 19,73 ±1,062mm in left eyes. In group 2, AL were detected 19,90± 0,83mm in right eyes and 19,86 ± 0,842mm in left eyes (p gt;0.05). In group1 and 2, SE values were detected 0.44±2.053D and -0.02±3.07D in right eyes and 0.59±2.063D and -0.17±2.8 in left eyesD, respectively ( p gt;0.05). There was no statistically significant differences between two groups about AL and SE values. Conclusion: Myopia is seen higher in patients with ROP than healthy patients. Although using anti vascular growth factor in ROP has been increased last years, diode laser photocoagulation is the gold standart therapy. In our study we compared the effects of diode laser photocoagulation and IVR on AL and SE. We did not find any statistically significant difference. Further evaluation is needed.
